JP2022536085A5 - - Google Patents
Info
- Publication number
- JP2022536085A5 JP2022536085A5 JP2021571911A JP2021571911A JP2022536085A5 JP 2022536085 A5 JP2022536085 A5 JP 2022536085A5 JP 2021571911 A JP2021571911 A JP 2021571911A JP 2021571911 A JP2021571911 A JP 2021571911A JP 2022536085 A5 JP2022536085 A5 JP 2022536085A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025133172A JP2026002847A (ja) | 2019-06-03 | 2025-08-08 | 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856264P | 2019-06-03 | 2019-06-03 | |
| US62/856,264 | 2019-06-03 | ||
| US201962914252P | 2019-10-11 | 2019-10-11 | |
| US62/914,252 | 2019-10-11 | ||
| US201962949817P | 2019-12-18 | 2019-12-18 | |
| US62/949,817 | 2019-12-18 | ||
| PCT/US2020/035811 WO2020247419A2 (en) | 2019-06-03 | 2020-06-03 | Oligonucleotides and methods of use for treating neurological diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025133172A Division JP2026002847A (ja) | 2019-06-03 | 2025-08-08 | 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022536085A JP2022536085A (ja) | 2022-08-12 |
| JPWO2020247419A5 JPWO2020247419A5 (https=) | 2023-06-06 |
| JP2022536085A5 true JP2022536085A5 (https=) | 2023-06-06 |
| JP7795914B2 JP7795914B2 (ja) | 2026-01-08 |
Family
ID=73653367
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571911A Active JP7795914B2 (ja) | 2019-06-03 | 2020-06-03 | 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法 |
| JP2025133172A Pending JP2026002847A (ja) | 2019-06-03 | 2025-08-08 | 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025133172A Pending JP2026002847A (ja) | 2019-06-03 | 2025-08-08 | 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220333105A1 (https=) |
| EP (1) | EP3976010A4 (https=) |
| JP (2) | JP7795914B2 (https=) |
| KR (1) | KR20220033472A (https=) |
| CN (1) | CN114555069A (https=) |
| AU (1) | AU2020288555A1 (https=) |
| BR (1) | BR112021024463A2 (https=) |
| CA (1) | CA3142526A1 (https=) |
| IL (1) | IL288574A (https=) |
| MX (1) | MX2021014868A (https=) |
| PH (1) | PH12021553024A1 (https=) |
| WO (1) | WO2020247419A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020150290A2 (en) | 2019-01-14 | 2020-07-23 | President And Fellows Of Harvard College | Methods and compositions for restoring stmn2 levels |
| EP4127172A4 (en) * | 2020-03-25 | 2025-06-04 | President and Fellows of Harvard College | Methods and compositions for restoring STMN2 levels |
| EP4162051A4 (en) * | 2020-06-03 | 2025-07-09 | Quralis Corp | TREATMENT OF NEUROLOGICAL DISEASES USING GENE TRANSCRIPT MODULATORS |
| WO2022018155A1 (en) * | 2020-07-23 | 2022-01-27 | F. Hoffmann-La Roche Ag | Lna oligonucleotides for splice modulation of stmn2 |
| WO2022018187A1 (en) * | 2020-07-23 | 2022-01-27 | F. Hoffmann-La Roche Ag | Oligonucleotides targeting rna binding protein sites |
| AU2022255175A1 (en) * | 2021-04-06 | 2023-11-23 | Trace Neuroscience, Inc. | Compositions and methods for treating tdp-43 proteinopathy |
| KR20240052763A (ko) * | 2021-08-11 | 2024-04-23 | 아버 바이오테크놀로지스, 인크. | 스타스민 2 (stmn2)를 표적화하는 rna 가이드를 포함하는 유전자 편집 시스템 및 이의 용도 |
| AU2022402929A1 (en) * | 2021-12-03 | 2024-06-13 | Quralis Corporation | Splice switcher antisense oligonucleotides with modified backbone chemistries |
| GB202208387D0 (en) * | 2022-06-08 | 2022-07-20 | Ucl Business Ltd | Modified U7 snRNA construct |
| GB202208384D0 (en) * | 2022-06-08 | 2022-07-20 | Ucl Business Ltd | Modified U7 snRNA construct |
| WO2024124203A2 (en) * | 2022-12-09 | 2024-06-13 | Auttx, Llc | Targeted treatment of spliceopathy-induced neurological disorders |
| WO2024173645A1 (en) * | 2023-02-15 | 2024-08-22 | Arbor Biotechnologies, Inc. | Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript |
| WO2025184347A1 (en) * | 2024-02-27 | 2025-09-04 | Emory University | Network analysis of the cerebrospinal fluid proteome of sporadic and familial forms of amyotrophic lateral sclerosis and methods of treatment of the same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6187545B1 (en) * | 2000-01-19 | 2001-02-13 | Isis Pharmaceuticals Inc. | Antisense modulation of pepck-cytosolic expression |
| AU2002224787A1 (en) * | 2000-10-23 | 2002-05-06 | Mermaid Pharmaceuticals Gmbh | Method for temporally controlling antisense-mediated gene inactivation |
| US20030104410A1 (en) * | 2001-03-16 | 2003-06-05 | Affymetrix, Inc. | Human microarray |
| JP2007104971A (ja) * | 2005-10-14 | 2007-04-26 | New Industry Research Organization | ミオスタチンのスプライシング制御アンチセンスオリゴヌクレオチド |
| EP1815863A1 (en) * | 2006-02-03 | 2007-08-08 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Use of TLR3 agonists for the treatment of neurodegenerative disorders |
| US20110286997A1 (en) * | 2007-03-13 | 2011-11-24 | Hakon Hakonarson | Genetic Alterations on Chromosome 16 and Methods of Use Thereof for the Diagnosis and Treatment of Type 1 Diabetes |
| CA2762987A1 (en) * | 2009-05-22 | 2010-11-25 | Joseph Collard | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
| WO2012005898A2 (en) * | 2010-06-15 | 2012-01-12 | Alnylam Pharmaceuticals, Inc. | Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof |
| WO2012177639A2 (en) * | 2011-06-22 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Bioprocessing and bioproduction using avian cell lines |
| EP2788487B1 (en) * | 2011-12-08 | 2018-04-04 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues targeting human lmna |
| ES2807379T3 (es) * | 2013-03-14 | 2021-02-22 | Ionis Pharmaceuticals Inc | Composiciones y métodos para regular la expresión de Tau |
| US20160235843A1 (en) * | 2013-10-03 | 2016-08-18 | The General Hospital Corporation | Methods for increasing neuronal survival |
| WO2016060919A1 (en) * | 2014-10-14 | 2016-04-21 | The Board Of Regents Of The University Of Texas System | Allele selective inhibition of mutant c9orf72 foci expression by duplex rnas targeting the expanded hexanucleotide repeat |
| WO2017079352A2 (en) * | 2015-11-04 | 2017-05-11 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting nlrp3 gene expression and uses thereof |
| CA3103429A1 (en) * | 2018-06-14 | 2019-12-19 | Don W. Cleveland | Compounds and methods for increasing stmn2 expression |
| EP4127172A4 (en) * | 2020-03-25 | 2025-06-04 | President and Fellows of Harvard College | Methods and compositions for restoring STMN2 levels |
-
2020
- 2020-06-03 JP JP2021571911A patent/JP7795914B2/ja active Active
- 2020-06-03 WO PCT/US2020/035811 patent/WO2020247419A2/en not_active Ceased
- 2020-06-03 US US17/616,350 patent/US20220333105A1/en active Pending
- 2020-06-03 EP EP20818770.8A patent/EP3976010A4/en active Pending
- 2020-06-03 MX MX2021014868A patent/MX2021014868A/es unknown
- 2020-06-03 AU AU2020288555A patent/AU2020288555A1/en active Pending
- 2020-06-03 CA CA3142526A patent/CA3142526A1/en active Pending
- 2020-06-03 BR BR112021024463A patent/BR112021024463A2/pt unknown
- 2020-06-03 CN CN202080054507.9A patent/CN114555069A/zh active Pending
- 2020-06-03 PH PH1/2021/553024A patent/PH12021553024A1/en unknown
- 2020-06-03 KR KR1020217043411A patent/KR20220033472A/ko active Pending
-
2021
- 2021-12-01 IL IL288574A patent/IL288574A/en unknown
-
2025
- 2025-08-08 JP JP2025133172A patent/JP2026002847A/ja active Pending